β-hydroxy-β-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia

International Journal of Oncology

Volumn 38, Issue 3, 2011, Pages 713-720

  Aversa, Zaira ^a   Bonetto, Andrea ^b   Costelli, Paola ^b   Minero, Valerio Giacomo ^b   Penna, Fabio ^b   Baccino, Francesco Maria ^b   Lucia, Simone ^a   Fanelli, Filippo Rossi ^a   Muscaritoli, Maurizio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

hydroxy methylbutyrate; Cachexia; Cancer; Muscle

Indexed keywords

4 EB P1 PROTEIN; ANABOLIC AGENT; BETA HYDROXY BETA METHYLBUTYRIC ACID; BUTYRIC ACID DERIVATIVE; INITIATION FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; P70S6K PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES HEPATOMA; BIOSYNTHESIS; BODY WEIGHT; CACHEXIA; CANCER CACHEXIA; CARCASS; CONTROLLED STUDY; DISEASE MODEL; FOOD INTAKE; GASTROCNEMIUS MUSCLE; HEART WEIGHT; LIVER WEIGHT; MALE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RAT; SOLEUS MUSCLE; SPLEEN WEIGHT; TUMOR GROWTH; WEIGHT REDUCTION; WESTERN BLOTTING;

ANIMALS; BODY WEIGHT; CACHEXIA; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; MALE; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RANDOM ALLOCATION; RATS; RATS, WISTAR; VALERATES; WEIGHT LOSS;

EID: 79952026816     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.885     Document Type: Article

References (43)

1. Muscaritoli M, Bossola M, Aversa Z, Bellantone R and Rossi Fanelli F: Prevention and treatment of cancer cachexia: new insight into an old problem. Eur J Cancer 42: 31-41, 2006. (Pubitemid 41814530)
2. MacDonald N, Easson AM and Mazurak VC, et al: Understanding and managing cancer cachexia. J Am Coll Surg 197: 143-161, 2003. (Pubitemid 36759189)
3. Costelli P and Baccino FM: Cancer cachexia: from experimental models to cancer patients. Curr Opin Clin Nutr Metab Care 60: 177-181, 2000. (Pubitemid 30469071)
4. Ciechanover A: The ubiquitin-proteasome proteolytic pathway. Cell 79: 13-21, 1994.
5. Kadovaki M and Kanazawa T: Amino acids as regulators of proteolysis. J Nutr 133 (Suppl. 6): S2052-S2056, 2003.
6. 2+-dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine 19: 1-5, 2002.
7. Du J, Wang X, Miereles C, Bailey JL, Debigare R and Zheng B: Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 113: 115-123, 2004. (Pubitemid 38541638)
8. Costelli P, Muscaritoli M, Bossola M, Penna F, Reffo P, Bonetto A, Busquets S, Bonelli G, Lopez-Soriano FJ, Doglietto GB, Argilés JM, Baccino FM and Rossi Fanelli F: IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol 291: R674-R683, 2006. (Pubitemid 44352350)
9. Costelli P, Muscaritoli M, Bonetto A, Penna F, Reffo P, Bossola M, Bonelli G, Doglietto GB, Baccino FM and Rossi Fanelli F: Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest 38: 531-538, 2008. (Pubitemid 351832040)
10. Nissen SL and Abumrad NN: Nutritional role of the leucine metabolite β-hydroxy-β-methylbutyrate (HMB). J Nutr Biochem 8: 300-311, 1997. (Pubitemid 27325823)
11. Frexes-Steed M, Lacy DB, Collins J and Bumrad NN: Role of leucine and other amino acids in regulating protein metabolism in vivo. Am J physiol 262: E925-E935, 1992.
12. Nissen S, Sharp R and May M, et al: Effect of leucine metabolite β-hydroxy-β-methylbutyrate on muscle metabolism during resistence exercise training. J Appl Physiol 81: 2095-2104, 1996. (Pubitemid 26384538)
13. Smith HJ, Wyke SM and Tisdale MJ: Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by β-hydroxy-β-methylbutyrate. Cancer Res 64: 8731-8735, 2004. (Pubitemid 39552090)
14. Paddon-Jones D, Sheffield-Moore M and Urban RJ, et al: Essential aminoacid and carbohydrate supplementation ameliorates muscle protein loss in humans during 28 days bedrest. J Clin Endocrinol Metab 89: 4531-4538, 2004.
15. Smith HJ, Mukerji P and Tisdale MJ: Attenuation of proteasome-induced proteolysis in skeletal muscle by β-hydroxy-β-methylbutyrate in cancer-induced muscle loss. Cancer Res 65: 277-283, 2005. (Pubitemid 40070819)
16. Eley HL, Russel ST, Baxter JH, Mukerji P and Tisdale MJ: Signaling pathways initiated by β-hydroxy-β-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli. Am J Physiol Metab 293: E923-E931, 2007. (Pubitemid 47535823)
17. Panton LB, Rathmacher JA, Baier S and Nissen S. Nutritional supplementation of the leucine metabolite β-hydroxy-β-methylbutyrate (HMB) during resistance training. Nutrition 16: 734-739, 2000.
18. Van Someren KA, Edwards AJ and Howatson G: Supplementation with beta-hydroxy-beta-methylbutyrate (HMB) and alphaketoisocaproic acid (KIC) reduces signs and symptoms of exercise-induced muscle damage in man. Int J Sport Nutr Exerc Metab 15: 413-424, 2005. (Pubitemid 41283877)
19. May PE, Barber A, D'Olimpio JT, Hourihane A, Naji N and Abumrad MD: Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate (HMB), arginine and glutamine. Am J Surg 183: 471-479, 2002. (Pubitemid 34442515)
20. Berk L, James J, Scwartz A, et al: A randomized, double-blind, placebo-controlled trial of a β-hydroxyl-β-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (ROTG 0122). Support Care Cancer 16: 1179-1188 2008.
21. Clark RH, Feleke G and Din M, et al: Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN Parenter Enter Nutr 24: 133-139, 2000.
22. Rathmacher JA, Nissen S and Panton L, et al: Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve haematological parameters. JPEN J Parenter Enter Nutr 28: 65-75, 2004. (Pubitemid 38365370)
23. Marcora S, Lemmey A and Maddison P: Dietary treatment of rheumatoid cachexia with beta-hydroxy-beta-methylbutyrate, glutamine and arginine: a randomised controlled trial. Clin Nutr 24: 442-454, 2005. (Pubitemid 40668432)
24. Kuhls DA, Rathmacher JA and Musngi MD, et al: β-hydroxy-β- methylbutyrate supplementation in critically ill trauma patients. J Trauma 62: 125-132, 2007.
25. Hsieh LC, Chien SL, Huang MS, Tseng HF and Chang CK: Anti-inflammatory and anticatabolic effects of short-term beta-hydroxy-beta-methylbutyrate supplementation on chronic obstructive pulmonary disease patients in intensive care unit. Asia Pac J Clin Nutr 15: 544-550, 2006.
26. Wilson GJ, Wilson JM and Manninem AH: Effects of beta-hydroxy-beta- methylbutyrate (HMB) on exercise performance and body composition across varying levels of age, sex and training experience: a review. Nutr Metab (Lond) 3: 1-17, 2008.
27. Gallagher PM, Carrithers JA, Godard MP, Schulze KE and Trappe SW: Beta-hydroxy-beta-methylbutyrate ingestion, part II: effect on hematology, hepatic and renal function. Med Sci Sports Exerc 32: 2116-2119, 2000.
28. Flakoll P, Sharp R, Baier S, Levenhagen D, Carr C and Nissen S: Effect of β-hydroxy-β-methylbutyrate, arginine, and lysine supplementation on strenght, functionality, body composition, and protein metabolism in elderly women. Nutrition 20: 445-451, 2004 (Pubitemid 38501798)
29. Nissen S, Sharp RL, Panton L, Vukovich M, Trappe S and Fuller JC Jr: β-hydroxy-β-methylbutyrate (HMB) supplementation in humans is safe and may decrease cardiovascuylar risk factors. J Nutr 130: 1937-1945, 2000.
30. Bachhawat BK, Robinson WG and Coon MJ: Enzymatic carboxylation of beta-hydroxyisovaleryl coenzyme A. J Biol Chem 219: 539-550, 1956.
31. Evans M and Rees A: Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 25: 649-663, 2002.
32. Daneryd P, Aberg F, Dallner G, Ernster L, Scherstén T and Soussi B: Coenzymes Q9 and Q10 in skeletal and cardiac muscle in tumour-bearing exercising rats. Eur J Cancer 31A: 760-765, 1995.
33. Folkers K and Simonsen R: Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochim Biophys Acta 1271: 281-286, 1995.
34. Gingras A-C, Raught B and Sonenberg N: eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Ann Rev Biochem 68: 913-963, 1999. (Pubitemid 29449212)
35. Shen W, Boyle DW, Wisniowski P, Bade A and Liechty A: Insulin and IGF-I stimulate the formation of the eukariotik initiation factor 4F complex and protein synthesis in C2C12 myotubes independent of availability of external amino acids. J Endocrinol 185: 275-289, 2005. (Pubitemid 40691794)
36. Price N and Proud C: The guanine nucleotide-exchange factor, eIF-2B. Biochimie 76: 748-760, 1994.
37. Jefferson LS, Fabian JR and Kiball SR: Glycogen synthase kinase-3 in the predominant insulin-regulated eukaryotic initiation factor 2B kinase in skeletal muscle. Int J Biochem Cell Biol 31: 191-200, 1999. (Pubitemid 29094799)
38. Rowlands AG, Panniers R and Henshaw EC: The catalytic mechanism of guanine nucleotide exchange factor action and competitive inhibition by phosphorylated eukaryotic initiation factor 2. J Biol chem 263: 5526-5533, 1998.
39. Tessitore L, Costelli P, Bonetti G and Baccino FM: Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch Biochem Biophys 306: 52-58, 1993. (Pubitemid 23291282)
40. Tessitore L, Bonelli G, Cecchini G, Amenta JS and Baccino FM: Regulation of protein turnover versus growth state: ascites hepatoma as a model for studies both in the animal and in vitro. Arch Biochem Biophys 255: 372-384, 1987.
41. Chaberge S, Cassarino E and Mangiarotti G: The phosphorylation of protein S6 modulates the interaction of the 40 S ribosomal subunit with the 5'-untranslated region of a dictyostelium prespore-specific mRNA and controls its stability. J Biol Chem 273: 27070-27075, 1998. (Pubitemid 28500411)
42. Muscaritoli M, Costelli P, Aversa Z, Bonetto A, Baccino FM and Rossi Fanelli F: New strategies to overcome cancer cachexia: from molecular mechanisms to the 'Parallel Pathway'. Asia Pac J Clin Nutr 17 (Suppl. 1): S387-S390, 2008.
43. Muscaritoli M, Molfino A, Gioia G, Laviano A and Rossi Fanelli F: The 'parallel pathway': a novel nutritional and metabolic approach to cancer patients. Intern Emerg Med, Jul 2, [Epub ahead of print], 2010.